Morgan Stanley analyst Judah Frommer lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $119.00 (from $123.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE